Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.18%
#3 CoW Protocol CoW Protocol +44.40%
#4 Glidr Glidr +36.87%
#5 Humanity Humanity +26.78%
#6 Walrus Walrus +24.24%
#7 Codatta Codatta +19.91%
#8 Enso Enso +18.69%
#9 Collector Crypt Collector Crypt +14.14%
#10 The Black Bull The Black Bull +13.35%
Coin of the day
EXOD EXOD
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited

ASLN
Kedudukan dalam Saham #37031
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the... ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions. The company is involved in a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., aimed at pioneering immuno-oncology therapeutics that target the AhR pathway. Furthermore, ASLAN maintains partnerships with various entities, including Almirall, Array BioPharma, and CSL Limited. Established in 2010, the company's headquarters are located in Singapore.
Harga Saham
$0.6
Disegerakkan terakhir: 2024-08-14
Modal Pasaran
$2.09M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
SG
Perdagangan ASLAN Pharmaceuticals Limited (ASLN)

Kategori

Healthcare
Nisbah P/E bagi ASLAN Pharmaceuticals Limited (ASLN)
Nisbah P/E pada August 2026 TTM: -0.06
Menurut laporan kewangan dan harga saham terkini ASLAN Pharmaceuticals Limited, nisbah P/E semasa (TTM) ialah -0.06. Pada akhir 2022, syarikat mempunyai nisbah P/E sebanyak -0.16.
Sejarah nisbah P/E bagi ASLAN Pharmaceuticals Limited dari 2014 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) -0.06 -7.00%
2023 -0.06 -60.23%
2022 -0.16 -76.75%
2021 -0.67 -46.50%
2020 -1.26 180.46%
2019 -0.45 -45.18%
2018 -0.82 -25.47%
2017 -1.10 -78.85%
2016 -5.19 249.89%
2015 -1.48 375.92%
2014 -0.31 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -52,430.29%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -54,973.12%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -33,040.86%
BE
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.